-
Patient Panel: The impact of living with a rare disorder
Moderated by Diane Edquist Dorman, a patient panel discusses the types of support that are meaningful to patients and caregivers living with a rare disorder.
-
Panel: A common goal of getting drugs to market faster, cheaper, and safer
A panel of Jayson Slotnik, Attorney, Foley Hoag, LLP, Washington, D.C.; Peter Saltonstall, President & CEO, National Organization for Rare Disorders and Michael McCaughan, Editor-in-Chief, Prevision Policy, LLC; moderated by Wayne Oliver, Vice President and Georgia Project leader, The Center for Health Transformation examines How Health Care Reform helps or hurts getting drugs to market faster, cheaper, and safer, and what should companies be doing to be prepared.
-
The Effect of REMS on Product Commercialization
David A. Galardi, Pharm.D., Commercialization, Apogenics Inc. gives a REMS overview with emphasis on commercialization and the fallacy of standardization.
-
Patient Centered Health Management
Doug Carlson, VP Health Management & Quality, Centric Health Resources, Inc. presents new models for delivering health management including HealthConnect: Centric’s new platform.
-
Pfizer, Inc.
Ed Mascioli, M.D., Vice President, BioTherapeutics R&D, Orphan and Genetic Diseases, Pfizer, Inc. reviews Pfizer’s past experience in discovering, developing, and commercializing therapies for rare diseases and how Pfizer is restructuring to position itself to compete in this marketplace.
-
Reimbursement Implications and Strategies for Distribution Model Options
Dean Erhardt, Principal, D2Pharma Consulting, LLC presents reimbursement care updates and trends related to orphan drugs and strategies for exclusive, limited, and open distribution models.
-
Manufacturer Viewpoints and Initiatives
Roger Garceau, M.D., FAAP, Senior Vice President, R&D and Chief Medical Officer, NPS Pharmaceuticals, Inc. explains why and how investing in the orphan drug marketplace makes sense with predictions on how innovation will take place in the rare disease market going forward.
-
2010 Ultra Orphan Conference Opening Remarks
Craig Kephart, President & CEO, Centric Health Resources, Inc. shares his conference opening remarks.
-
Getting the Product to the Patient – Who is taking care of your customer?
Craig Kephart, President & CEO, Centric Health Resources, Inc. articulates ways to get your patient strategy aligned with patient needs, incentives and channel partners.
-
Big or Small: Drug Development Post-Health Care Reform
Michael McCaughan, Editor in Chief, Prevision Policy, LLC, explains what Health Care Reform does (and doesn’t) change about drug development, how FDA regulation is evolving at the same time and where we are headed next.
-
New Complexities in Pricing Orphan and Ultra-Orphan Drugs
Doug Paul, Partner, MME LLC elaborates how increased competition and changes in markets are pushing ultra-orphan drug prices downward.
-
Patient Centered Health Management/REMS 2.0
David Sirois, DMD, PhD, President of the Board of Directors, International Pemphigus & Pemphigoid Foundation (IPPF) discusses outcomes of a model for improving Ultra-Orphan illness through an individualized Health Management Program.
-
21st Century Medicine: The Promise and the Problems
Dr. Andy von Eschenbach, Senior Director for Strategic Initiatives, Center for Health Transformation, discusses the implications for the health care delivery system when medicine is personalized, predictive, preemptive and participatory, and the benefits of developing the structural and functional changes required across the spectrum of discovery–development–delivery to bring the fruits of R&D to patients.
-
Selling in a Competitive Ultra-Orphan Disease Market
Bill Zabel, Vice President, U.S. Sales, Talecris Biotherapeutics tells us about leveraging distribution to maximize outcomes by using patient advocates to raise disease awareness and managed care strategies to gain buy-in and support.
-
Health 2.0 – How Empowering Patients can Lead to Increased Patient Acquisition
Wendy White, President, Siren Interactive – Social networking and how to use it to reach patients. Presentation from the Centric Health Resources Ultra-Orphan Conference 2009. (Length 39:02)
-
The New Administration and the Impact on Orphan Drug Development
Jayson Slotnick, M.P.H., Esq., Hogan & Hartson – A health reform status update. Presentation from the Centric Health Resources Ultra-Orphan Conference 2009. (Length 29:25)
-
Including Distribution and Patient Services in Ultra-Orphan Pricing
Doug Paul, PharmD, MS, Medical Marketing Economics, LLC – The intersection of the forgotten P’s of the marketing mix.” What is the Missing P? Patients! Presentation from the Centric Health Resources Ultra-Orphan Conference 2009. (Length 38:04)
-
Why Smaller Is Better – The Triumph of the Biotech Model
Michael McCaughan, Editor- in-Chief, FDC-Windhover Biopharma Group – An eye-opening overview of the new FDA, with its tougher enforcement tools and how the new regulatory model favors the smaller, more nimble “biotech” organization. Presentation from the Centric Health Resources Ultra-Orphan Conference 2009. (Length 45:25)
-
Reimbursement and Benefit Trends
Dennis Matheis, President, Anthem Blue Cross and Blue Shield in Missouri – An overview of current reimbursement trends. Presentation from the Centric Health Resources Ultra-Orphan Conference 2009. (Length 39:45)
-
Integrate Risk Evaluation & Mitigation Strategies (REMS) with Health Management & Distribution
Craig Kephart, President & CEO, Centric Health Resources – The benefits of integrating REMS requirements with distribution. Presentation from the Centric Health Resources Ultra-Orphan Conference 2009. (Length 56:18)
